Valuation: Protara Therapeutics, Inc.

Market Cap 180M 159M 150M 136M 256M 17.28B 259M 1.8B 692M 8.83B 677M 662M 28.33B P/E 2026 *
-2.2x
P/E 2027 * -1.99x
Enterprise Value 180M 159M 150M 136M 256M 17.28B 259M 1.8B 692M 8.83B 677M 662M 28.33B EV / Sales 2026 *
-
EV / Sales 2027 * 180x
Free-Float
97.7%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Protara Therapeutics, Inc.

1 day-4.98%
1 week-13.84%
1 month-20.98%
3 months-20.16%
6 months-41.46%
Current year-42.78%
1 week 2.98
Extreme 2.98
3.44
1 month 2.98
Extreme 2.98
4.02
Current year 2.98
Extreme 2.98
7.5
1 year 2.98
Extreme 2.98
7.82
3 years 1.04
Extreme 1.04
10.48
5 years 1.04
Extreme 1.04
10.48
10 years 1.04
Extreme 1.04
67.08
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 45 2019-02-28
Chief Executive Officer 54 2017-10-31
Director of Finance/CFO 58 2023-01-29
Director TitleAgeSince
Chairman 67 2019-12-31
Director/Board Member 68 2019-12-31
Director/Board Member 60 2019-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Don

Founder

-30,000 0.0534%
6/15/26 Free

Director

31,000 0.0552%
6/15/26 Free

Director

31,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
-4.98%-13.84%-29.89%+82.63% 190M
+4.16%-0.36%+49.37%+94.17% 71.53B
-0.19%+1.32%+37.20%+83.85% 60.12B
-1.51%+2.39%+9.10%+35.15% 48.85B
-0.05%+0.37%+41.54%+36.65% 44.28B
+0.38%+7.61%+339.53%+641.55% 43.83B
+0.18%+0.26%+7.41%+103.45% 41.53B
-0.67%+0.17%+7.60%+46.37% 30.13B
+4.77%+6.16%+36.77%+22.78% 27.98B
-1.29%-3.55%-20.74%+352.04% 25.25B
Average +0.08%-0.22%+47.79%+149.86% 39.37B
Weighted average by Cap. +0.80%+1.37%+60.88%+148.52%

Financials

2026 *2027 *
Net sales - 1M 881K 834K 753K 1.42M 95.88M 1.44M 9.98M 3.84M 49.02M 3.76M 3.67M 157M
Net income -85.87M -75.62M -71.64M -64.68M -122M -8.23B -123M -857M -330M -4.21B -322M -315M -13.49B -108M -94.96M -89.97M -81.23M -153M -10.34B -155M -1.08B -414M -5.29B -405M -396M -16.95B
Net Debt - -
Logo Protara Therapeutics, Inc.
Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing transformative therapies for people with cancer and rare diseases. The Company's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin, as well as a Phase II trial in pediatric patients with LMs. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes. Additionally, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes.
Employees
46
Date Price Change Volume
26-09-30 US$3.050 -4.98% 8,824,550
26-09-29 US$3.210 -1.23% 391,465
26-09-28 US$3.250 -0.91% 431,134
26-09-25 US$3.280 -2.09% 552,942
26-09-24 US$3.350 -5.37% 661,970
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.050USD
Average target price
25.71USD
Spread / Average Target
+743.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TARA Stock